チェプラファーム株式会社 News Releases

Completion of Marketing Authorization Transfer for Myoclonus Treatment "Myocarm® Oral Solution 33.3%"

Cheplapharm K.K. announced the completion of the marketing authorization transfer for the myoclonus … · 2026-04-01

Completion of Marketing Authorization Transfer for Myoclonus Treatment "Myocarm® Oral Solution 33.3%"

Cheplapharm K.K. announced the completion of the marketing authorization transfer for the myoclonus … · 2026-04-01

Completion of Marketing Authorization Transfer for Myoclonus Treatment "Myocarm® Oral Solution 33.3%"

Cheplapharm K.K. announced the completion of the marketing authorization transfer for the myoclonus … · 2026-04-01